is the fda going to ban semaglutide says 'no clinical need' for compounded weight loss drugs Compounded Semaglutide Manufacturing Ban

Potential for type 2 diabetes and obesity treatment : Retatrutide is being studied for its effectiveness in treating both type 2 diabetes and obesity, offering hope for broader use in metabolic health

This ensures maximum absorption and immediate availability to the cells that need it most

The initial numbers are something weve never seen - Up to 24.3% weight loss via weekly injection at 36 weeks Around 13% weight loss via the oral form at just 12 weeks No weight loss plateau seen These results are faster than anything we currently have

But you should pay close attention to how you feel

2024;doi:10.1016/j.cgh.2024.03.013

prausnitzii may ultimately enhance butyrate production (42)